Journal
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY
Volume 46, Issue 6, Pages 2078-2089Publisher
OXFORD UNIV PRESS
DOI: 10.1093/ije/dyx207
Keywords
Mendelian randomization; pharmacovigilance; drug repurposing; adverse drug events
Categories
Funding
- Perros Trust
- MRC Integrative Epidemiology Unit
- Medical Research Council
- University of Bristol [MC_UU_12013/1, MC_UU_12013/9]
- MRC [MC_UU_12013/9, MC_UU_12013/1] Funding Source: UKRI
- Medical Research Council [MC_UU_12013/1, MC_UU_12013/9] Funding Source: researchfish
Ask authors/readers for more resources
Identification of unintended drug effects, specifically drug repurposing opportunities and adverse drug events, maximizes the benefit of a drug and protects the health of patients. However, current observational research methods are subject to several biases. These include confounding by indication, reverse causality and missing data. We propose that Mendelian randomization (MR) offers a novel approach for the prediction of unintended drug effects. In particular, we advocate the synthesis of evidence from this method and other approaches, in the spirit of triangulation, to improve causal inferences concerning drug effects. MR addresses some of the limitations associated with the existing methods in this field. Furthermore, it can be applied either before or after approval of the drug, and could therefore prevent the potentially harmful exposure of patients in clinical trials and beyond. The potential of MR as a pharmacovigilance and drug repurposing tool is yet to be realized, and could both help prevent adverse drug events and identify novel indications for existing drugs in the future.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available